Oral TJ 48 for interferon-α-2b/ribavirin-associated anaemia
1
Reactions 1042 - 12 Mar 2005 Oral TJ 48 for interferon-α-2b/ ribavirin-associated anaemia Oral TJ 48 therapy appears to reduce the anaemia associated with interferon-α-2b [Intron-A] and ribavirin [Rebetol] combination therapy in patients with chronic hepatitis C virus (HCV) infection, according to researchers from Japan. They investigated the effect of TJ 48 use on interferon- α-2b/ribavirin-associated anaemia in 67 such patients, aged < 70 years, who had haemoglobin levels of ≥ 13 mg/dL. The patients received ribavirin (800 mg/day for patients ≥ 60kg, 600 mg/day for patients < 60kg) for 24 weeks and interferon-α-2b 6 MU/day for 2 weeks, then three times weekly for 22 weeks, either with (n = 32) or without (35) TJ 48 7.5 g/day initiated 1–4 weeks before, or at the time of, treatment initiation. At 4, 8 and 12 weeks of therapy, the reduction in haemoglobin levels was significantly less in patients who received TJ 48 than in patients who did not receive TJ 48. Significantly less patients who received TJ 48 required reduction or withdrawal of ribavirin because of severe anaemia than patients who did not receive TJ 48 (13% vs 43%). Sho Y, et al. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C. Journal of Gastroenterology 39: 1202-1204, No. 12, Dec 2004 801003446 1 Reactions 12 Mar 2005 No. 1042 0114-9954/10/1042-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Oral TJ 48 for interferon-α-2b/ribavirin-associated anaemia
Reactions 1042 - 12 Mar 2005
Oral TJ 48 for interferon-α-2b/ribavirin-associated anaemia
Oral TJ 48 therapy appears to reduce the anaemiaassociated with interferon-α-2b [Intron-A] and ribavirin[Rebetol] combination therapy in patients with chronichepatitis C virus (HCV) infection, according toresearchers from Japan.
They investigated the effect of TJ 48 use on interferon-α-2b/ribavirin-associated anaemia in 67 such patients,aged < 70 years, who had haemoglobin levels of≥ 13 mg/dL. The patients received ribavirin (800 mg/dayfor patients ≥ 60kg, 600 mg/day for patients < 60kg) for24 weeks and interferon-α-2b 6 MU/day for 2 weeks,then three times weekly for 22 weeks, either with(n = 32) or without (35) TJ 48 7.5 g/day initiated1–4 weeks before, or at the time of, treatment initiation.
At 4, 8 and 12 weeks of therapy, the reduction inhaemoglobin levels was significantly less in patientswho received TJ 48 than in patients who did not receiveTJ 48. Significantly less patients who received TJ 48required reduction or withdrawal of ribavirin because ofsevere anaemia than patients who did not receive TJ 48(13% vs 43%).Sho Y, et al. Orally administered Kampo medicine, Juzen-taiho-to, amelioratesanemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.Journal of Gastroenterology 39: 1202-1204, No. 12, Dec 2004 801003446
1
Reactions 12 Mar 2005 No. 10420114-9954/10/1042-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
